Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of hESC-derived Mesenchymal Cells for Intrauterine Adhesions
NCT04232592Phase 1Unknown
- Start
- Jan 2020
- Primary completion
- Jan 2022
- Modality
- Stem Cell Therapies
01
Overview
Phase 1, open-label trial of hESC-derived mesenchymal cells in Intrauterine Adhesions (IUA) (2 arms). Primary endpoint: Incidence of different Adverse Events of transplantation of mesenchymal cells from human embryonic stem cells at 48 weeks. Status: unknown.
02
Drugs
hESC-derived mesenchymal cells
03
Conditions
Intrauterine Adhesions (IUA)
Beyond the preview
Go deeper on NCT04232592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04232592.